GlassScriptPhysician profile
Jennifer Natashsa David
NPI 1740571496
$34,513.12
in general payments reported to CMS, 2019-2025
33 companies · $6,828 in 2025
The $6,828 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,024 · 2020: $135 · 2021: $1,543 · 2022: $3,631 · 2023: $6,244 · 2024: $15K · 2025: $6,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $8,409 · Travel and Lodging: $1,225 · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,162.00 |
| Food and Beverage | $8,408.75 |
| Travel and Lodging | $1,224.70 |
| Education | $384.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $19,612.51 | 2023-2025 | Zoryve |
| Abbvie INC. | $3,579.42 | 2019-2025 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $1,945.80 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $1,643.10 | 2020-2025 | Tremfya |
| Genzyme Corporation | $909.70 | 2021-2025 | |
| Lilly USA, LLC | $760.55 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $750.32 | 2019-2025 | Ilumya |
| Galderma Laboratories, L.P. | $687.26 | 2019-2025 | Nemluvio, Epsolay |
| Hill Dermaceuticals, INC. | $573.15 | 2024-2025 | Tolak |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $565.16 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $495.92 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $493.47 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $376.20 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $319.76 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $256.91 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $239.70 | 2019-2021 | |
| Organogenesis INC. | $224.83 | 2024-2025 | Apligraf, Puraply Am |
| Pfizer INC. | $223.03 | 2024-2025 | |
| Amgen INC. | $209.41 | 2022-2025 | Otezla, Otezla |
| Allergan, INC. | $148.39 | 2019-2022 | |
| Journey Medical Corporation | $124.11 | 2019-2022 | |
| Dermavant Sciences, INC. | $83.36 | 2023-2024 | Vtama |
| Encore Dermatology INC. | $52.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.02 | 2024-2025 | Spevigo |
| Epi Health, LLC | $34.81 | 2019-2022 | |
| Integra Lifesciences Corporation | $28.53 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Celgene Corporation | $27.20 | 2019 | |
| Botanix Sb INC | $23.01 | 2025 | Sofdra |
| Exact Sciences Corporation | $19.70 | 2024 | Cologuard Collection Kit |
| Dermira, INC. | $17.74 | 2021 | |
| Organon LLC | $16.11 | 2025 | Vtama |
| Novo Nordisk INC | $14.48 | 2024 | |
| Mayne Pharma Commercial LLC | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.